


PHARMACEUTICAL 2022

AGILE THERAPEUTICS INC Rank 428 of 466









PHARMACEUTICAL 2022

AGILE THERAPEUTICS INC Rank 428 of 466



The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 88% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 173% points.

The company's Economic Capital Ratio, given in the ranking table, is -170%, being 248% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	23,925
Cost of Goods Sold	10,718
Intangible Assets	0
Liabilities, Current	29,278
Liabilities, Non-Current	784
Other Assets	2,961
Other Compr. Net Income	-3.0
Other Expenses	43,444
Other Liabilities	0
Other Net Income	-3,889
Other Revenues	4,101
Property and Equipment	12,447
Research and Development	6,246
Selling, General and Administrative Expense	14,698

Output Variable	Value in 1000 USD
Assets	39,333
Liabilities	30,062
Expenses	75,106
Revenues	4,101
Stockholders Equity	9,271
Net Income	-74,894
Comprehensive Net Income	-74,896
Economic Capital Ratio	-170%

